Table 49. Patient characteristics–trifluoperazine versus clozapine

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Rinieris et al. 1980**157 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Schizophrenia  ***DSM Classification:*** NR  ***Study period:*** NR  ***Number of centers:*** Single center  ***Setting:*** Inpatient  ***Country:*** Greece  ***Financial support:*** NR  ***Washout period performed:*** NA  ***Run-in phase performed:*** yes (1 wk)  ***Followup period:*** 6 wks | ***Main inclusion criteria:*** Sz pts with absence of clinical symptoms; no Hx of thyroid or endocrinological disease; no use of psychotropic meds  ***Main exclusion criteria:*** NR | ***G1:***  ***Age (mean±SD):*** 27.30±9.00  ***Males (n(%)):*** NR  ***Ethnicity:*** NR  ***BL symptom scores:*** BPRS (mean±SD): 41.5±9.3  ***G2:***  ***Age (mean±SD):*** 27.30±9.00  ***Males (n(%)):*** NR  ***Ethnicity:*** NR  ***BL symptom scores:*** BPRS (mean±SD): 40.5±10  ***G3:***  ***Age (mean±SD):*** 27.30±9.00  ***Males (n(%)):*** NR  ***Ethnicity:*** NR  ***BL symptom scores:*** BPRS (mean±SD): 36.4±11.4 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Chlorpromazine  ***Dosage:*** 50–100mg  ***Intervals:*** TID  ***G2:***  ***Classification:*** FGA  ***Drug:*** Trifluoperazine  ***Dosage:*** 2.5–5mg  ***Intervals:*** TID  ***G3:***  ***Classification:*** SGA  ***Drug:*** Clozapine  ***Dosage:*** 50–100mg  ***Intervals:*** TID |

AP = antipsychotic; BL = baseline; BPRS = Brief Psychiatric Rating Scale; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; DX = diagnosis; FGA = first-generation antipsychotic; Hx = history; mg = milligram; n = number; NR = not reported; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; TID = Three times daily; wk = week; yr = year